Venus Remedies' Q1 FY 2025-26 Quarterly Results

Result Summary

• Venus Remedies Ltd reported a 29.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 27.6%.
• Its expenses for the quarter were down by 29.5% QoQ and up 23.8% YoY.
• The net profit decreased 8.7% QoQ and increased 686.9% YoY.
• The earnings per share (EPS) of Venus Remedies Ltd stood at 7.2 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Venus Remedies Ltd is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products. With a focus on specialty drugs, the company operates primarily in the healthcare and pharmaceutical industry. Its product portfolio spans oncology drugs, antibiotics, and critical care drugs, addressing both domestic and international markets. In recent developments, the company has been expanding its reach by entering new markets and enhancing its product offerings. However, specific recent developments for Venus Remedies Ltd are not available within the provided data.

Revenue

The financial performance of Venus Remedies Ltd for Q1FY26 shows a total income of ₹140.59 crores. This represents a quarter-over-quarter (QoQ) decrease of 29.4% compared to Q4FY25, where the total income was ₹199.08 crores. On a year-over-year (YoY) basis, there is an increase of 27.6% from Q1FY25, which recorded a total income of ₹110.20 crores. The significant YoY growth indicates increased business activities or higher sales compared to the same quarter in the previous fiscal year, despite the QoQ decline.

Profitability

Profitability for Venus Remedies Ltd in Q1FY26 is notable with a Profit Before Tax (PBT) of ₹12.60 crores. This reflects a QoQ decrease of 27.9% from ₹17.47 crores in Q4FY25. However, when compared to Q1FY25, there is an 83.9% YoY increase from ₹6.85 crores. The Profit After Tax (PAT) for Q1FY26 is ₹9.60 crores, showing an 8.7% decrease from the preceding quarter's PAT of ₹10.51 crores. Compared to the same period in the previous fiscal year (Q1FY25), where the PAT was ₹1.22 crores, there is a substantial YoY increase of 686.9%. The Earnings Per Share (EPS) for Q1FY26 is ₹7.20, which decreased by 8.9% QoQ but increased by 700.0% YoY compared to ₹0.90 in Q1FY25.

Operating Metrics

Total expenses for Venus Remedies Ltd in Q1FY26 amounted to ₹127.99 crores, which is a 29.5% reduction from ₹181.61 crores in Q4FY25. This represents a 23.8% increase from the expenses of ₹103.35 crores in Q1FY25. The tax paid in Q1FY26 is ₹3.00 crores, significantly lower by 56.9% QoQ from ₹6.96 crores in Q4FY25 and a 46.7% decrease YoY from ₹5.63 crores in Q1FY25. These financial metrics provide a snapshot of the company's operational efficiency and cost management over the given periods.